Sequence 39 from Patent US 20120328692

General Information


DRACP ID  DRACP01458

Peptide Name   Sequence 39 from Patent US 20120328692

Sequence  TNWYANXEKLLR

Sequence Length  12

UniProt ID  Not available

PubChem CID  Not available

Origin  Synthetic construct

Type  Synthetic peptide

Classification

  

Active ACP



Activity Information


Hemolytic Activity  Not available

Normal (non-cancerous) Cytotoxicity  Not available

Target  Not available

Affinity  Not available

Mechanism  Not available

Nature  Anticancer



Structure Information


PDB ID  Not available

Predicted Structure  Not available

Helicity  Not available

Linear/Cyclic  Not available

Disulfide/Other Bond  Not available

N-terminal Modification  Not available

C-terminal Modification  Not available

Other Modification  X = Leu with F, Cl, Br, I, CH3, CF3, CN, OH, or NO2 at positions gamma, delta1 or delta2

Chiral  L



Physicochemical Information


Formula  C64H96N18O17

Absent amino acids  CDFGHIMPQSV

Common amino acids  LN

Mass  169596

Pl  9.3

Basic residues  2

Acidic residues  1

Hydrophobic residues  4

Net charge  1

Boman Index  -2929

Hydrophobicity  -103.33

Aliphatic Index  73.33

Half Life 
  /

Extinction Coefficient cystines  6990

Absorbance 280nm  635.45

Polar residues  4

Amino acid distribution



Literature Information


Literature 1

Pubmed ID Not available

Title  Not available

Doi Not available

Year  Not available

Patent

Patent ID US 2012/0328692 A1

Patent Title  Potent D-peptide antagonists of mdm2 and mdmx for anticancer therapy.

Other Iinformation  Granted Patent Family: 8s / 8ex; Family Jurisdictions: CN, DK, US, EP, ES; Legal Status: Active; Application No: 16168397; Filed:May 4, 2016; Published: Jul 17, 2019; Earliest Priority: May 7, 2015; Granted: Jul 17, 2019

Other Published ID  Not available




DRACP is developed by Dr.Zheng's team.